Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells
- PMID: 17082574
- DOI: 10.4049/jimmunol.177.10.6626
Prime-boost with alternating DNA vaccines designed to engage different antigen presentation pathways generates high frequencies of peptide-specific CD8+ T cells
Abstract
The route for presentation of Ag to CD8+ or CD4+ T cells following DNA vaccination is critical for determining outcome, but the pathways involved are unclear. In this study, we compare two different DNA vaccine designs aimed to elicit CD8+ T cell responses against a specific peptide-epitope either by direct- or cross-presentation. Each carries sequences from tetanus toxin (TT) to provide essential CD4+ T cell help. In the first already proven design, the peptide-epitope is fused to the N-terminal domain of fragment C from TT. This appears to act mainly by cross-presentation. In the second design, the peptide-epitope is encoded by a minigene, with induction of Th responses mediated by coexpression of a hybrid invariant chain molecule, incorporating a single determinant from TT (p30) in exchange for class II-associated invariant chain peptide. This design appears to act mainly via direct presentation from transfected APCs. Both vaccines mediated Th-dependent priming of CD8+ T cells in mice, but the kinetics and level of the responses differed markedly, consistent with engagement of distinct pathways of Ag presentation. Importantly, the vaccines could be combined in an alternating prime-boost regime, in either order, generating substantially expanded memory CD8+ T cells, with potent effector function. Taken together, these results demonstrate that vaccination protocols involving different modes of Ag presentation at prime and boost can significantly improve the effectiveness of immunization.
Similar articles
-
DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.J Immunol. 2004 Oct 1;173(7):4492-9. doi: 10.4049/jimmunol.173.7.4492. J Immunol. 2004. PMID: 15383580
-
CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.J Immunother. 2010 Jun;33(5):510-22. doi: 10.1097/CJI.0b013e3181d75cef. J Immunother. 2010. PMID: 20463596
-
Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides.J Immunol. 2003 Aug 1;171(3):1240-6. doi: 10.4049/jimmunol.171.3.1240. J Immunol. 2003. PMID: 12874211
-
Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.Expert Opin Biol Ther. 2006 Dec;6(12):1311-21. doi: 10.1517/14712598.6.12.1311. Expert Opin Biol Ther. 2006. PMID: 17223739 Review.
-
Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.Immunol Rev. 1999 Aug;170:29-38. doi: 10.1111/j.1600-065x.1999.tb01326.x. Immunol Rev. 1999. PMID: 10566139 Review.
Cited by
-
Methods for improving the immunogenicity and efficacy of cancer vaccines.Expert Opin Biol Ther. 2018 Jul;18(7):765-784. doi: 10.1080/14712598.2018.1485649. Epub 2018 Jun 17. Expert Opin Biol Ther. 2018. PMID: 29874943 Free PMC article. Review.
-
CD8+ T-cell cross-competition is governed by peptide-MHC class I stability.Eur J Immunol. 2012 Jan;42(1):256-63. doi: 10.1002/eji.201142010. Epub 2011 Nov 28. Eur J Immunol. 2012. PMID: 22002320 Free PMC article.
-
Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine.PLoS One. 2012;7(9):e43730. doi: 10.1371/journal.pone.0043730. Epub 2012 Sep 6. PLoS One. 2012. PMID: 22970140 Free PMC article.
-
Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.PLoS One. 2010 Jun 30;5(6):e11406. doi: 10.1371/journal.pone.0011406. PLoS One. 2010. PMID: 20613977 Free PMC article.
-
A DNA Vaccine Against Proadrenomedullin N-Terminal 20 Peptide (PAMP) Reduces Angiogenesis and Increases Lymphocyte and Macrophage Infiltration but Has No Effect on Tumor Burden in a Mouse Model of Lung Metastasis.Vaccines (Basel). 2025 May 30;13(6):586. doi: 10.3390/vaccines13060586. Vaccines (Basel). 2025. PMID: 40573917 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous